Minovia Therapeutics appoints Maha Radhakrishnan, Chief Medical Officer at Biogen, as board member
TIRAT HACARMEL, Israel, Jan. 05, 2023, a clinical-stage company focused on developing novel Mitochondrial Augmentation Technology (MAT) to fight mitochondrial diseases, has announced a Board appointment. Maha
United States Natalie Yivgi Ohana Astellas Pharma Maha Radhakrishnan Mitochondrial Augmentation Technology Bristol Myers Squibb
Source: finanznachrichten.de